KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Boston Scientific (BSX) EBIT (2016 - 2025)

Boston Scientific's EBIT history spans 17 years, with the latest figure at $825.0 million for Q4 2025.

  • For Q4 2025, EBIT rose 22.22% year-over-year to $825.0 million; the TTM value through Dec 2025 reached $3.6 billion, up 38.8%, while the annual FY2025 figure was $3.6 billion, 38.8% up from the prior year.
  • EBIT for Q4 2025 was $825.0 million at Boston Scientific, down from $1.0 billion in the prior quarter.
  • Across five years, EBIT topped out at $1.0 billion in Q3 2025 and bottomed at $180.0 million in Q4 2021.
  • The 5-year median for EBIT is $536.0 million (2023), against an average of $570.4 million.
  • The largest annual shift saw EBIT skyrocketed 469.01% in 2021 before it dropped 7.49% in 2022.
  • A 5-year view of EBIT shows it stood at $180.0 million in 2021, then skyrocketed by 123.33% to $402.0 million in 2022, then soared by 45.27% to $584.0 million in 2023, then grew by 15.58% to $675.0 million in 2024, then increased by 22.22% to $825.0 million in 2025.
  • Per Business Quant, the three most recent readings for BSX's EBIT are $825.0 million (Q4 2025), $1.0 billion (Q3 2025), and $819.0 million (Q2 2025).